Biologics Inspection Case Studies Highlight API and Drug Product Deficiencies

Conference Spotlight

Facility Issues Top Inspection Deficiencies for Biologics

Conference Spotlight

Who is Responsible When GMPs Are Not Followed?

Conference Spotlight

What is a VAI or OAI Regulatory Meeting?

Conference Spotlight

Drug GMP Warning Letter Issued Without Facility Inspection

Enforcement

Expert Commentary | Updates to FDA’s Manual of Policies and Procedures (MAPP)

Conference Spotlight

FDA on the Evolution of Biologics Inspections: Part II

Conference Spotlight

Persistent Non-Compliance Leads to a Consent Decree

Conference Spotlight

Senior Management Failures Lead to Patient Deaths, Prison Sentence

Why am I Being Inspected Again So Soon After a Pre-Approval Inspection?

Conference Spotlight

Five FDA Warning Letters Issued in Four Years for Fraudulent Cancer Drug